NIPT

Yourgene said it continues to consider additional acquisition opportunities to enhance its earnings and to acquire complementary technologies.

The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.

The company said three clinical centers have validated the test in a prospective clinical trial involving more than 10,000 participants.

The Unity test enables screening for several autosomal recessive conditions from fetal DNA gathered from maternal blood.

The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.

The nonpartisan federal agency's report suggests ways for Congress, the FDA, FTC, and CMS to expand oversight of the genetic testing market.

The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.